The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the ...

A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...

A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...

The typical treatment for estrogen receptor positive (ER+) breast cancer involves surgery and years of hormone therapy that ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

Maintaining treatment with CDK4/6 inhibitors significantly suppresses the growth of breast cancer cells, even after drug resistance has developed, according to new research.

Astra is due to pay Daiichi US$175 million in milestones after the US approval, the companies said. Enhertu is cleared in the ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...